Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

High blood pressure can indirectly cause shortness of breath by forcing the heart to work harder, which may lead to cardiovascular issues. Pulmonary hypertension, a specific type of high blood ...

Pulmonary thromboendarterectomy is a surgery used to treat chronic thromboembolic pulmonary hypertension. It’s the treatment of choice for this condition. Chronic thromboembolic pulmonary hypertension ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Pulmonary arterial hypertension is a progressive disease involving proliferative remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated morbidity and mortality ...

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study. The combination is ...

Researchers estimate that about 1% of the global population has pulmonary hypertension — a disease caused by high blood pressure in the blood vessels that deliver oxygen to the lungs. Past studies ...